BioMarin Pharmaceutical ( NASDAQ:BMRN – Get Rating ) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided EPS guidance of $1.80-$2.05 for the period, compared to the consensus EPS estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.46 billion. BioMarin Pharmaceutical Price Performance Shares of NASDAQ BMRN traded up $3.59 during trading on Friday, reaching $96.04. The company had a trading volume of 1,739,425 shares, compared to its average volume of 1,089,845.

https://www.dailypolitical.com/2023/04/30/biomarin-pharmaceutical-nasdaqbmrn-issues-fy-2023-earnings-guidance.html

#dailypolitical